EUVIMEDEUVIMED entdecken
Crossref

Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study

Franz J. Legat, Christian Vestergaard, Julien Seneschal, Stephan Weidinger, Andreas Wollenberg, Alan Irvine, Helena Agell, Júlia Valls Bancells, Victor Sapena, Diamant Thaçi

Skin · 09.11.2026 · 2026 (4) · 86-114

DOI: 10.61783/oegdv11214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Skin, online erschienen am 09.11.2026. Verfasst von Franz J. Legat und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Legat, F. J., Vestergaard, C., Seneschal, J., Weidinger, S., Wollenberg, A., Irvine, A., Agell, H., Bancells, J. V., Sapena, V., & Thaçi, D. (2026). Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study. Skin, 2026(4), 86-114. https://doi.org/10.61783/oegdv11214

Vancouver

Legat FJ, Vestergaard C, Seneschal J, Weidinger S, Wollenberg A, Irvine A, et al. Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study. Skin. 2026;2026(4):86-114. doi:10.61783/oegdv11214

BibTeX
@article{Legat2026,
  author = {Legat, Franz J. and Vestergaard, Christian and Seneschal, Julien and Weidinger, Stephan and Wollenberg, Andreas and Irvine, Alan and Agell, Helena and Bancells, Júlia Valls and Sapena, Victor and Thaçi, Diamant},
  title = {Lebrikizumab provides clinically meaningful response in face and hands in adults and adolescents with moderate-to-severe atopic dermatitis: ADhope 1 study},
  journal = {Skin},
  year = {2026},
  volume = {2026},
  number = {4},
  pages = {86--114},
  doi = {10.61783/oegdv11214}
}
Kostenlos starten →